27.11.2024 13:34:07
|
EQS-Adhoc: Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action Korneuburg, Austria, 27. November 2024 - Marinomed Biotech AG (the “Company”) announces that it has signed a binding term sheet with the European Investment Bank (EIB) for the intended issuance of a convertible bond (registered bond in the name or order) with a nominal value of EUR 423,840, which is to be subscribed exclusively by the European Investment Bank (EIB) (excluding the statutory subscription rights of existing shareholders) against the contribution of a right of segregation. The convertible bond will evidence a conversion right in initially up to 84,768 shares of the Company at a conversion price of EUR 5 per share and will be issued in December 2024. In the event of conversion of the convertible bond, it is intended to issue the shares available from the conditional capital of the Company. A corresponding report on the planned exclusion of the statutory subscription rights of existing shareholders to convertible bonds will be published shortly. The required resolution of the Supervisory Board on the issuance of the convertible bond with the exclusion of subscription rights can be adopted at the earliest two weeks after publication of the report. The necessary consent of the insolvency administrator for the issuance of the convertible bond has not yet been obtained.
+++ End of ad-hoc announcement +++ End of Inside Information
27-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com |
Language: | English |
Company: | Marinomed Biotech AG |
Hovengasse 25 | |
2100 Korneuburg | |
Austria | |
Phone: | +43 2262 90300 |
E-mail: | office@marinomed.com |
Internet: | www.marinomed.com |
ISIN: | ATMARINOMED6 |
WKN: | A2N9MM |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
EQS News ID: | 2039579 |
End of Announcement | EQS News Service |
|
2039579 27-Nov-2024 CET/CEST
Nachrichten zu Marinomed Biotech AG
23.12.24 |
ATX Prime-Handel aktuell: ATX Prime mittags in Grün (finanzen.ch) | |
20.12.24 |
Pluszeichen in Wien: Zum Ende des Freitagshandels Pluszeichen im ATX Prime (finanzen.ch) | |
20.12.24 |
Schwacher Handel: ATX Prime verbucht Abschläge (finanzen.ch) | |
20.12.24 |
ATX Prime-Handel aktuell: So bewegt sich der ATX Prime mittags (finanzen.ch) | |
20.12.24 |
Anleger in Wien halten sich zurück: ATX Prime beginnt Handel in der Verlustzone (finanzen.ch) | |
19.12.24 |
Börse Wien in Rot: ATX Prime gibt letztendlich nach (finanzen.ch) | |
19.12.24 |
ATX Prime-Handel aktuell: ATX Prime gibt am Nachmittag nach (finanzen.ch) | |
19.12.24 |
EQS-News: Marinomed Biotech AG: Außerordentliche Hauptversammlung stimmt Veräußerung des Carragelose-Geschäftsbereichs zu (EQS Group) |
Analysen zu Marinomed Biotech AG
Jahresrückblick & Jahresausblick 2024/2025 – Wall Street Live mit Tim Schäfer
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Vorweihnachtliche Zurückhaltung: SMI schlussendlich im Plus -- DAX geht schwächer aus dem HandelDer heimische Aktienmarkt schloss am Montag im Plus, wohingegen sich der deutsche Aktienmarkt abwärts bewegte.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |